STOCK TITAN
  1. Home
  2. Sec-filings
  3. AMGN
  4. [Form 4] AMGEN INC Insider Trading Activity

Amgen (NASDAQ: AMGN) EVP Santos receives 11,259-share stock award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Santos Esteban reported acquisition or exercise transactions in this Form 4 filing.

Amgen executive Esteban Santos reported an equity award of 11,259 shares of common stock granted on 2026-03-03. The grant was recorded at a stated price of $0.00 per share as a stock award, bringing his directly held Amgen shares to 87,877.

The direct holdings figure includes 624 Dividend Equivalents credited under Amgen’s 2009 Equity Incentive Plan, which pay out in common stock as related RSUs vest, with cash paid for any remaining fractional share amount. Separately, Santos has indirect holdings representing 903.8036 shares through the company’s 401(k) plan stock fund.

Positive

  • None.

Negative

  • None.
Insider Santos Esteban
Role EVP, Operations
Type Security Shares Price Value
Grant/Award Common Stock 11,259 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 87,877 shares (Direct); Common Stock — 903.804 shares (Indirect, 401K Plan)
Footnotes (1)
  1. These shares include 624 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. These shares are acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Santos Esteban
(Last) (First) (Middle)
ONE AMGEN CENTER DRIVE
(Street)
THOUSAND OAKS CA 91320-1799
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Operations
3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/03/2026 A 11,259 A $0 87,877(1) D
Common Stock 903.8036(2) I 401K Plan
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These shares include 624 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
2. These shares are acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.
/s/ Esteban Santos 03/04/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Amgen (AMGN) EVP Esteban Santos report in this Form 4 filing?

Amgen EVP Esteban Santos reported receiving an equity award of 11,259 shares of common stock. The award was recorded at a stated price of $0.00 per share, increasing his directly held position to 87,877 shares, plus additional indirect holdings through the company 401(k) plan.

How many Amgen (AMGN) shares does Esteban Santos now hold directly?

After the reported equity award, Esteban Santos directly holds 87,877 Amgen common shares. This figure includes 624 Dividend Equivalents tied to unvested RSUs, which will be settled in shares as those RSUs vest, with cash paid out for any remaining fractional share amounts.

What are the 624 Dividend Equivalents mentioned in the Amgen (AMGN) Form 4?

The 624 Dividend Equivalents are credits granted under Amgen’s 2009 Equity Incentive Plan to Santos’ unvested RSUs. They are paid out in Amgen common stock on a one-to-one basis as the related RSUs vest, along with a cash payment covering any remaining fractional share portion.

How are Esteban Santos’ indirect Amgen (AMGN) holdings structured in this Form 4?

Santos’ indirect holdings are through Amgen’s 401(k) Plan, representing interests equal to 903.8036 shares in the company’s stock fund. These plan-based interests reflect retirement account ownership, separate from his directly held award and RSU-related Dividend Equivalents reported in the same Form 4 filing.

Was the 11,259-share Amgen (AMGN) award a market purchase by Esteban Santos?

No, the 11,259 shares reflect a grant or award acquisition, not an open-market purchase. The transaction code indicates a grant at a stated price of $0.00 per share, consistent with stock-based compensation rather than buying shares in the public market.